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Case report
Nephrotic syndrome as a clinical manifestation of graft-versus-host
disease (GVHD) in a marrow transplant recipient after cyclosporine
withdrawal
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Departments of 1Hematology 2Pathology and 3Nephrology, EPM/UNIFESP, Sa˜o Paulo, Brazil
Summary:
GVHD is one of the most frequent complications of
BMT and recently nephrotic syndrome (NS) has been
described as a manifestation of chronic GVHD. Here,
we present an AA patient who developed NS 1 year
after BMT when cyclosporine was stopped. Renal
biopsy showed focal sclerosis associated with membra-
nous deposits. He also had other clinical manifestations
of chronic GVHD: sicca-like syndrome and colestasis.
After 15 days of CsA therapy, he experienced a remark-
able improvement in the NS and GVHD as a whole. We
comment on immunological mechanisms that could be
involved in the pathogenesis of this manifestation.
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Case report
Chronic graft-versus-host disease (GVHD) is one of the
most frequent complications after bone marrow transplan-
tation (BMT). It is immune-mediated and involves auto-
antibodies generated by T-lymphocyte donor reactivity to
major histocompatibility complex (MHC) minor anti-
gens.1,2 Nephrotic syndrome (NS) has been described as
one of the clinical forms of chronic GVHD or as part of
this clinical syndrome. Membranous glomerulonephritis has
been found in the majority of patients and one case has
described minimal change nephrotic syndrome.3–7 Here, we
present a typical case of NS, with an unusual morphological
feature in the setting of well-documented chronic GVHD.
A 26-year-old white man with AAS underwent a related
identical HLA BMT in January 1994. He received ATG
(90 mg/kg) and cyclophosphamide (200 mg/kg), as con-
ditioning and short-term MTX plus cyclosporine (CsA) as
GVHD prophylaxis, without any evidence of acute or
chronic GVHD. CsA was tapered 180 days after BMT and
withdrawn after 1 year. After 1 month, he presented with
Correspondence: JSR Oliveira, Disciplina de Hematologia, Universidade
Federal de Sa˜o Paulo, Escola Paulista de Medicina, Rua Botucatu 740,
CEP 04023-900, Brazil
Received 6 April 1998; accepted 15 August 1998
conjunctival hyperemia and a month later, he developed
clinical nephrotic syndrome with a 24-h urine protein of
3.64 g/dl, serum albumin of 1.4 and antinuclear antibody
titer of 1:160 with normal renal function (serum creatinine,
0.8 mg/dl and creatinine clearance, 120 ml/h). Opthalmol-
ogical evaluation confirmed GVHD syndrome involving
both eyes, as a sicca-like syndrome. He was treated with
prednisone (40 mg daily) with clinical improvement. Two
months later, he presented with a total 24-h urine protein of
14.5 g/dl and serum albumin of 1.79 g/dl, pleural effusion,
elevation of hepatic enzymes and colestasis (AST, 200 U/l;
ALT, 448 U/l; ALP 756 U/l; GGT, 50 IU/l; total bilirubin
1.2 U/l). Serology for hepatitis B and C virus was negative,
as were CMV antigen levels (monoclonal antibodies against
pt65-core virus protein). Cyclosporine was started
(3.5 mg/kg twice daily) and resulted in decreasing pro-
teinuria, regression of pleural effusions and absence of anti-
nuclear antibodies, while hepatic colestasis (ALT, 207 U/l;
AST, 88 U/l; ALP, 700 U/l; GGT, 439 U/l) was maintained
as the only sign of GVHD.
The patient was treated with CsA and prednisone
(20 mg/day) for 8 months and, currently, he has no clinical
or laboratory features of GVHD, a negative 24-h urine pro-
tein and normal hepatic enzymes and renal function (serum
creatinine 0.8 mg/dl; urea nitrogen 28 mg/dl; AST 40 U/l;
ALT 38 U/l; GGT 37 U/l; ALP 337 U/l; total bilirubin
1.8 U/l).
During his illness he underwent two liver and renal
biopsies, the first at diagnosis and the second 5 months
later.
Pathologic features
On light microscopy, the features of the first renal biopsy
were compatible with minimal change nephrotic syndrome.
There were eight normal glomeruli. Glomerular tufts con-
tained dilated capillaries, glomerular basement membrane
was not thickened and glomerular cellularity was within the
normal range, with swollen and prominent visceral epi-
thelial cells. Tubular and interstitial blood vessels were
unremarkable. The second biopsy showed features consist-
ent with focal and segmental glomerular sclerosis. The
biopsy included 12 glomeruli, with the presence of
localized areas of sclerosis in two of them. These are as
occurred in the Hilary location and collapse of capillaries,
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Figure 1 Segmental glomerular sclerosis close to the vascular pole. Note
collapse of vascular spaces adjacent to synechiae (HE; 100· ).
Figure 2 Segmental glomerular sclerosis. Two peripheral areas (Jones
methenamine silver; 100· ).
expansion of the mesangial matrix and adhesion to Bow-
man’s capsule were present. The remaining part of the
biopsy showed features similar to the first one (Figures 1
and 2). On electron microscopy, focal effacement of the
foot processes and electron dense deposits on basement
glomerular membranes were observed (Figure 3). Liver
biopsy showed the histological findings of GVHD; immu-
nohistochemistry for hepatisis virus B infection (HBsAg
and HBcAg) was negative.
Discussion
We describe a patient who underwent BMT for AAS and
who received CsA plus MTX as GVHD prophylaxis. He
developed NS after CsA withdrawal, as his first manifes-
tation of chronic GVHD. He differs from previous reports,
where NS was preceded by acute GVHD. He was treated
with prednisone without clinical improvement and
developed pleural effusions, progressive colestasis and pro-
teinuria. After 2 weeks of CsA, he experienced a remark-
able improvement of both NS and GVHD.
Figure 3 Electron dense deposits within the epimembranous space
(arrows). Note focal effacement of the foot process (electron micro-
graph, 750 · ).
It is well established that immunological factors are
involved in the development of GVHD such as: (1) donor
T-lymphocyte cytokine release which may change glomeru-
lar permeability; and (2) minor disparities between donor
and recipient MHC, responsible for the GVHD phenom-
enon as a whole.8,9 The clear improvement of NS is due to
CsA inhibition of interleukin and interferon gamma pro-
duction by donor T-lymphocytes, which may be responsible
for the glomerular permeability alterations in NS.
The seccond biopsy, performed 5 months later, showed
segmental sclerosis and also membranous nephropathy.
Although auto-antibodies have not been consistently
present in all cases described in the literature, circulating
or in situ immune complexes are responsible for the fea-
tures of membranous nephropathy as demonstrated here.
However, cellular mechanisms may be implicated as seg-
mental sclerosis also was seen. Immunosuppression can
easily control these manifestations and follow-up of such
patients requires careful evaluation of their immunological
status and CsA should be always tapered slowly to avoid
the immune-mediated problems described above.
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